Moderna announced Tuesday its coronavirus vaccine was 100% effective in a study of adolescents ages 12 to 17 and will seek emergency use approval from the Food and Drug Administration early next month.
The drugmaker’s vaccine, if approved would be the second behind the Pfizer/BioNTech vaccine to get clearance for use in adolescents.
The Moderna study covered more than 3,700 adolescents. No cases of the virus were observed in the participants who received two doses of the vaccine, while four cases were seen in the placebo group, the company said.
Additionally, no significant side effects were identified among the participants that were not uncommon to adults, the company said.
“We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,” Moderna CEO Stephane Bancel said in a statement. “We remain committed to doing our part to help end the COVID-19 pandemic.”
The two-dose Pfizer/BioNTech vaccine, the first to come out for adults in December, was cleared for 12-to-15-year-olds earlier this month.